Abpro Corporation initiated with a Buy at Maxim

Maxim initiated coverage of Abpro Corporation (ABP) with a Buy rating and $4 price target The company leverages its DiversImmune and MultiMab discovery and engineering platforms to generate bispecific antibodies with advantages in affinity, avidity, selectivity, pharmacokinetic or PK/safety profiles, and structural design, the analyst tells investors in a research note. The bispecific antibody space continues to evolve rapidly, particularly in solid tumors and ophthalmology, and the value propositions in both of these categories are substantial, with rising valuations, high-value M&A activity, and capital inflows, Maxim notes, adding that as an early-stage company, Abpro has largely gone unnoticed since recently emerging into the public market.